Search Results
Aug 18, 2026, 08:10 ET Consano Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica
treatments for chronic sciatica despite its prevalence and widespread societal and economic impact.About C-1101C-1101 is Consano Bio's lead investigational clinical candidate and the first pharmaceutical therapy of its kind in development: a novel, platelet-derived multi-protein biologic
More news about: Consano Bio
Aug 18, 2026, 08:04 ET Evogene Reports Second Quarter and First Half 2026 Financial Results
financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as
More news about: Evogene
Aug 17, 2026, 09:00 ET Slingshot Bio Launches ViaComp® Ultra Amine: A Next-Generation Cell Mimic for Amine-Reactive Viability and Antibody Compensation in Multiparameter Flow Cytometry
including lot-to-lot variability, resource-intensive maintenance, limited availability for rare biomarkers, and regulatory burden.Slingshot Bio's cell mimic platform addresses these challenges by combining the biological relevance of cell-based controls with the precision, reproducibility, and
More news about: Slingshot Bio
Aug 11, 2026, 14:02 ET FirmGuard Introduces SecureReset: Pre-OS, Remote Endpoint Wipe and Reimage for Incident Response
BEAVERTON, Ore., Aug. 11, 2026 /PRNewswire/ -- FirmGuard, a leader in UEFI BIOS firmware security, management and incident response, today announced the launch of SecureReset, a groundbreaking new capability that enables
More news about: FirmGuard
Aug 11, 2026, 07:00 ET Transpire Bio's Dr. Lei Mao Appointed as Board Chair of the IPAC-RS for its 2026-2028 Term
biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, last week announced that Lei Mao, PhD, Transpire Bio's Head of External Research, has been elected to the position of Board Chair of the International Pharmaceutical Aerosol Consortium on Regulation &
More news about: Transpire Bio
Aug 10, 2026, 10:00 ET Lifespan Vision Ventures Leads Remedium Bio's Series A Financing
multimedia:https://www.prnewswire.co.uk/news-releases/lifespan-vision-ventures-leads-remedium-bios-series-a-financing-302847043.html
More news about: LifeSpan Vision Ventures
Aug 10, 2026, 10:00 ET Lifespan Vision Ventures Leads Remedium Bio's Series A Financing
multimedia:https://www.prnewswire.com/news-releases/lifespan-vision-ventures-leads-remedium-bios-series-a-financing-302847038.htmlSOURCE
More news about: LifeSpan Vision Ventures
Aug 06, 2026, 16:01 ET HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by
More news about: Halozyme Therapeutics, Inc.
Aug 06, 2026, 11:00 ET SEAN PAUL, DISCLOSURE AND TWO FRIENDS TO HEADLINE T-MOBILE STAGE DURING FORMULA 1 HEINEKEN LAS VEGAS GRAND PRIX 2026, NOVEMBER 19-21
here for assets and artist biosLAS VEGAS, Aug. 6, 2026 /PRNewswire/ -- The
More news about: FORMULA 1 HEINEKEN LAS VEGAS GRAND PRIX
Aug 06, 2026, 10:31 ET The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
to improve patient convenience, particularly by enabling potential subcutaneous delivery and faster amyloid plaque clearance.Annovis Bio's BuntanetapTranslational Inhibitor of Neurotoxic Aggregating Proteins (TINAPs)Buntanetap (previously known as ANVS401 or
More news about: DelveInsight Business Research, LLP
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
therapeutic and commercial potential, Nuvation Bio's belief that IBTROZI is becoming the standard of care in advanced ROS1+ NSCLC, Nuvation Bio's plans to evaluate safusidenib across the broad spectrum of patients with IDH-1mutant glioma, and Nuvation Bio's evaluation of additional preclinical candidates
More news about: Nuvation Bio, Inc.
Aug 05, 2026, 12:15 ET GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation
Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proofPISCATAWAY, N.J. and SAN FRANCISCO, Aug.
More news about: GenScript Biotech Corporation
Aug 05, 2026, 12:15 ET GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation
Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proofPISCATAWAY, N.J. and SAN FRANCISCO, Aug.
More news about: GenScript Biotech Corporation
Aug 05, 2026, 09:30 ET 1Elevan Biopharmaceuticals Is Building the Infrastructure to Be the Partner of Choice for Peptide Medicine
continuity and a secure, legal source, we are positioned to help offer that."The investment beyond compounding capabilities signals 1Elevan Bio's commitment to supporting the entire patient journey. Practically, that means securing American manufacturing, engaging providers, and ensuring tailored
More news about: 1Elevan Bio
Aug 05, 2026, 06:59 ET Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2a clinical trial, Q32 Bio's expectations and assumptions regarding the timing of reporting the findings from the Part B OLE of the SIGNAL-AA Phase 2a clinical trial, the expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of Q32 Bio's product candidates, including
More news about: Q32 Bio
Aug 05, 2026, 03:00 ET NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
promising therapies more efficiently to reach patients faster."Renowned University of Pennsylvania Professor, Dr. Bruce Levine, a member of NueCell Bio's Scientific Advisory Board, said, "The ecosystem of advanced therapies I have been part of for many years is moving rapidly and NueCell Bio helps meet
More news about: NueCell Bio
Aug 05, 2026, 03:00 ET NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
promising therapies more efficiently to reach patients faster."Renowned University of Pennsylvania Professor, Dr. Bruce Levine, a member of NueCell Bio's Scientific Advisory Board, said, "The ecosystem of advanced therapies I have been part of for many years is moving rapidly and NueCell Bio helps meet
More news about: NueCell Bio
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Publications section of Nuvation Bio's website after the presentations. To meet representatives from Nuvation Bio, visit Booth #115 at WCLC and Booth #1080 at ESMO.About ROS1+ NSCLCEach
More news about: Nuvation Bio Inc.
Aug 03, 2026, 08:00 ET Cizzle Bio Expands Access to Early Lung Cancer Detection Through Strategic Laboratory Collaboration with BioBridge Global in South Texas
the terms of the agreement, BBG Advanced Therapies, a subsidiary of nonprofit BBG, will serve as a CLIA-certified laboratory partner offering Cizzle Bio's CIZ1B Biomarker Blood Test for Lung Cancer to licensed healthcare providers across South Texas.Because CIZ1B is a laboratory-developed test (LDT),
More news about: Cizzle Bio
Jul 30, 2026, 09:03 ET NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.
multimedia:https://www.prnewswire.com/news-releases/ns-pharma-parent-company-nippon-shinyaku-exercises-option-rights-for-commercialization-of-ab2-bios-tadekinig-alfa-in-the-us-302838606.htmlSOURCE
More news about: NS Pharma, Inc.
Jul 29, 2026, 15:00 ET Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
The financing is expected to extend Entera Bio's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH (1-34) peptide tablet in development for the treatment
More news about: Greenberg Traurig, LLP
Jul 29, 2026, 07:06 ET Flex Announces Leadership Teams for Flex and Planned Cloud and Power Infrastructure Spin-Off (SpinCo)
Executive Bios page.About Flex Flex (Reg. No. 199002645H) is the manufacturing partner of choice that helps leading brands design, build, and
More news about: Flex
Jul 28, 2026, 13:00 ET F1 BUSINESS SUMMIT RETURNS TO FORMULA 1 HEINEKEN LAS VEGAS GRAND PRIX WEEKEND, NOVEMBER 19
here for assets, headshots and biosLAS VEGAS, July 28, 2026 /PRNewswire/ -- Formula 1® has announced
More news about: FORMULA 1 HEINEKEN LAS VEGAS GRAND PRIX
Jul 23, 2026, 14:30 ET AMI Announces AMI Rack Manager Support for AMD Helios Rackscale Solution and Aptio V and MegaRAC OneTree Support for 6th Gen AMD EPYC Processors, Accelerating Deployment for AI Data Centers Worldwide
Aptio® V BIOS/UEFI firmware and
More news about: AMI
Jul 23, 2026, 08:30 ET Halozyme to Report Second Quarter 2026 Financial and Operating Results
settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®
More news about: Halozyme Therapeutics, Inc.